Biotech Values

[bladerunner1717]

Ignyta (RXDX) prices public offering


SAN DIEGO--(BUSINESS WIRE)--

Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a precision oncology biotechnology company, today announced the pricing of an underwritten public offering of 4,285,714 shares of its common stock at a price to the public of $17.50 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta. Ignyta has granted the underwriters a 30-day option to purchase up to an additional 642,857 shares of common stock in connection with the offering. The offering is expected to close on or about June 16, 2015, subject to customary closing conditions.

Ignyta anticipates using the net proceeds from the offering to fund research and development activities for its development programs and for working capital and general corporate purposes.

Credit Suisse Securities (USA) LLC, Jefferies LLC, Leerink Partners LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering and Cantor Fitzgerald & Co. and Ladenburg Thalmann are acting as co-managers.

The shares described above are being offered by Ignyta pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Ignyta with the Securities and Exchange Commission (the “SEC”) and that was declared effective on March 13, 2015. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, or by calling toll-free [phone] or emailing a request to [e-mail]; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling [phone] or emailing a request to [e-mail]; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling [phone] ext. 6142 or emailing a request to [e-mail]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by calling [phone] or emailing a request to [e-mail].




Ignyta, Inc., located in San Diego, California, is a precision oncology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The company's goal with this Rx/Dx approach is to discover, develop and commercialize new drugs that target activated cancer genes and pathways for the customized treatment of cancer, as well as novel chemotherapeutics that can potentially provide additional benefit to cancer patients. It aims to achieve this goal by pairing its product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients who are most likely to benefit from the precisely targeted drugs the company develops.


Bladerunner